论文部分内容阅读
目的:探讨雷贝拉唑联合替普瑞酮治疗慢性胃炎的临床疗效。方法:选取2014年10月-2016年1月在我院接受治疗的慢性胃炎患者78例,并根据治疗方法不同分为观察组和对照组各39例,对照组采用替普瑞酮进行治疗,观察组采用雷贝拉唑、替普瑞酮联合治疗,观察并比较两组的治疗效果。结果:观察组治疗总i有效率94.9%明显高于对照组的71.8%,P<0.05,有统计学意义;观察组患者腹胀、上腹疼痛、反酸消失时间明显短于对照组,治疗后两组患者胃黏膜组织慢性炎症评分、活动性炎症评分均降低,降低幅度观察组明显优于对照组,P<0.05,有统计学意义。结论:雷贝拉唑联合替普瑞酮治疗慢性胃炎疗效显著,可有效改善患者的临床症状,促进胃黏膜修复。
Objective: To investigate the clinical efficacy of rabeprazole and teprenone in the treatment of chronic gastritis. Methods: From October 2014 to January 2016, 78 patients with chronic gastritis who were treated in our hospital were selected and divided into observation group (39 cases) and control group (39 cases) according to different treatment methods. The control group was treated with teprenone, The observation group was treated with rabeprazole and teprenone, and the therapeutic effect was observed and compared between the two groups. Results: The effective rate of total i in the observation group was significantly higher than that of the control group (94.9% vs 71.8%, P <0.05). The observation group had shorter bloating, upper abdominal pain and disappearance of acid reflux than the control group. Chronic inflammatory score and active inflammation scores of gastric mucosal tissue in both groups were decreased, and the decrease in the observation group was better than that in the control group (P <0.05), which was statistically significant. Conclusion: Rabeprazole and teprenone are effective in treating chronic gastritis, which can effectively improve the clinical symptoms and promote the repair of gastric mucosa.